Our Humira-Watch continues as a flood of biosimilars hit the market. Some of these drug options cost 85% less than Humira.
Humira Competition Begins
Amjevita, the first biosimilar competitor to Humira hit the U.S. market at the end of January. Showcasing the dysfunction of our healthcare delivery system, the copycat drug came to market with two drastically different list prices. One, a mere 5% discount relative to Humira and another with a 55% discount. Why two prices and who would pay for the more expensive option?
